Research programme: multiple sclerosis therapy - Quigley PharmaAlternative Names: QR-442
Latest Information Update: 20 Feb 2008
At a glance
- Originator Quigley Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 27 Oct 2005 Preclinical trials in Multiple sclerosis in USA (unspecified route)